NCT03078322: A trial that was reported late by VistaGen Therapeutics, Inc.
This trial has reported, although it was 518 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03078322 |
|---|---|
| Title | Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 5, 2018 |
| Completion date | Oct. 1, 2019 |
| Required reporting date | Sept. 30, 2020, midnight |
| Actual reporting date | March 3, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 518 |